NCT06156644Not yet recruiting
Pulsed-Field-Ablation to Treat Atrial fiBRillation With a novEl multimodalIty Generator
Source: ClinicalTrials.gov · Last updated 3 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this first-in-human clinical trial a novel generator (INTELLAPULSE), designed and built by Stockert, which supports highly flexible PFA protocols as well as RF interventions will be used. For 12 months and follow-up for 12 months, after a 3-months blanking period 50 consecutive paroxysmal AF patients, eligible for catheter ablation, will be enrolled.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 13 Nov 2023
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- University Hospital Freiburg
- Diseases
- Atrial fibrillation
- NCT number
- NCT06156644
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Jul 2025 to the primary completion date, 1 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous left atrial ablation
- unable to receive ablation therapy
Age
- age \<18 years
Other
- lack or withdrawal of written informed consent
Who the study is looking for
- new onset atrial fibrillation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.